Lophius Biosciences GmbH aus Regensburg auf der MEDICA 2017 in Düsseldorf -- COMPAMED Messe

Lophius Biosciences GmbH

Am Biopark 13, 93053 Regensburg
Deutschland

Telefon +49 941 63091970
Fax +49 941 63091979
request@lophius.com

Dieser Aussteller ist Mitaussteller von
Bayern Innovativ GmbH

Hallenplan

MEDICA 2017 Hallenplan (Halle 3): Stand E83

Geländeplan

MEDICA 2017 Geländeplan: Halle 3

Ansprechpartner

Bernd Merkl

CEO / Managing Director

Dr. Andreas Anger

Senior Product Manager

Unser Angebot

Produktkategorien

  • 03  Diagnostika
  • 03.05  Infektionsimmunologie
  • 03.05.05  Mikrobiologische Diagnostik / Virologie, Geräte und Systeme für die

Mikrobiologische Diagnostik / Virologie, Geräte und Systeme für die

Unsere Produkte

Produktkategorie: Mikrobiologische Diagnostik / Virologie, Geräte und Systeme für die

T-Track® CMV - in vitro diagnostic kit

Lophius Biosciences is a privately-held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases. The company’s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation and Reverse T Cell Technology platforms.
With its T-Track® CMV leading product, Lophius offers a highly sensitive, reliable and standardized CE-marked in vitro diagnostic solution to measure the functionality of CMV-specific cell-mediated immunity. T-Track® CMV assists clinicians in the risk stratification of CMV disease in immunocompromised patients, toward an improved and individualized patient management.

Lophius Biosciences is always interested in collaborating with distribution partners for our in vitro diagnostic ELISpot kit T-Track® CMV in various regions of the world.

Mehr Weniger

Über uns

Firmenporträt

Lophius Biosciences is a privately-held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases.

The company’s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation and Reverse T Cell Technology platforms. Whereas the T-activation technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics.  

With its T-Track® CMV leading product, based on T-activation technology, Lophius offers a highly sensitive, reliable and standardized CE-marked in vitro diagnostic solution to measure the functionality of CMV-specific cell-mediated immunity. T-Track® CMV assists clinicians in the risk stratification of CMV disease in immunocompromised patients, toward an improved and individualized patient management.

Mehr Weniger

Unternehmensdaten

Geschäftsfelder

Diagnostika

Firmeninfo als PDF